Dr. Goldfischer highlights the value of PSMA-PET imaging in urology
“PSMA scanning is definitely a game-changer with regard to imaging in advanced prostate cancer in urology,” says Evan R. Goldfischer, MD.
In this interview, Evan R. Goldfischer, MD, MBA, FACS, discusses the value of PSMA-PET imaging in prostate cancer. Goldfischer chaired a discussion on the rapidly emeging modalitiy during the 2022 LUGPA Annual Meeting in Chicago, Illinois. Goldfischer is the director of the Research Department at Premier Medical Group in Poughkeepsie, New York, and new LUGPA president.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
